What do systematic reviews say?

PDEI vs placebo

PDEI may leads to higher adverse events compared with placebo (low certainty).

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  RR 1.42 [1.21, 1.67]
  11 studies · 4386 participants
  Low

PDEI vs alpha‐blocker

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 933 participants
  Moderate

PDEI vs alpha‐blocker

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 550 participants
  Low

PDEI vs alpha‐blocker

PDEI showed no clear difference in adverse events compared with alpha‐blockers (low certainty).

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  RR 1.35 [0.8, 2.3]
  4 studies · 786 participants
  Low

PDEI plus alpha‐blocker vs alpha‐blocker

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 193 participants
  Low

PDEI plus alpha‐blocker vs alpha‐blocker

The review found no eligible studies for this question.

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

PDEI plus alpha‐blocker vs alpha‐blocker

PDEI plus alpha‐blocker probably leads to higher adverse effects compared with alpha‐blockers alone (moderate certainty).

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  RR 2.81 [1.53, 5.17]
  4 studies · 194 participants
  Moderate

Intervention not reported

• Cholinesterase inhibitors for rarer dementias associated with neurological conditions 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 24 participants
  Low

Intervention not reported

• Cholinesterase inhibitors for rarer dementias associated with neurological conditions 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 60 participants
  Low

Intervention not reported

• Cholinesterase inhibitors for rarer dementias associated with neurological conditions 2015 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 270 participants
  High

Intervention not reported

The intervention showed no clear difference in clinical global impression of change ‐ patient's self‐reported… (high certainty).

• Cholinesterase inhibitors for rarer dementias associated with neurological conditions 2015 · Cochrane Headline outcomes only
  OR 1.67 [0.93, 3]
  2 studies · 189 participants
  High

Intervention not reported

The intervention showed no clear difference in clinical global impression of change ‐ patient's self‐reported… (high certainty).

• Cholinesterase inhibitors for rarer dementias associated with neurological conditions 2015 · Cochrane Headline outcomes only
  OR 0.95 [0.45, 1.98]
  1 study · 120 participants
  High

Intervention not reported

The intervention showed no clear difference in clinical global impression of change ‐ clinician's impression of… (moderate certainty).

• Cholinesterase inhibitors for rarer dementias associated with neurological conditions 2015 · Cochrane Headline outcomes only
  OR 1.95 [0.88, 4.3]
  1 study · 120 participants
  Moderate

Intervention not reported

The intervention leads to higher clinical global impression of change ‐ clinician's impression of… (high certainty).

• Cholinesterase inhibitors for rarer dementias associated with neurological conditions 2015 · Cochrane Headline outcomes only
  OR 1.96 [1.06, 3.62]
  2 studies · 189 participants
  High

Intervention not reported

• Cholinesterase inhibitors for rarer dementias associated with neurological conditions 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 81 participants
  Low

Intervention not reported

• Cholinesterase inhibitors for rarer dementias associated with neurological conditions 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 161 participants
  High

Intervention not reported

• Cholinesterase inhibitors for rarer dementias associated with neurological conditions 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 161 participants
  High

Intervention not reported

• Cholinesterase inhibitors for rarer dementias associated with neurological conditions 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 161 participants
  Moderate

Intervention not reported

• Cholinesterase inhibitors for rarer dementias associated with neurological conditions 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 24 participants
  Low

Intervention not reported

The intervention leads to higher nausea (high certainty).

• Cholinesterase inhibitors for rarer dementias associated with neurological conditions 2015 · Cochrane Headline outcomes only
  OR 2.1 [1.22, 3.62]
  6 studies · 503 participants
  High